Impella CP with SmartAssist™ Experience Inder Singh, MD, MS, interventional cardiologist at Dignity Heart & Vascular discusses the Impella CP with SmartAssistTM technology and his team’s experience during the limited market release. The latest innovation on the Impella platform integrates the trusted performance of the Impella CP heart pump with state-of-the-art SmartAssist™ technology. This next … Continue reading “Quick Tips: Impella CP with SmartAssist™”
Use this patient transfer checklist and documentation when transferring a patient supported with an Impella® device from the “Spoke” hospital to the “Hub” hospital. Completing the patient transfer checklist ensures the best possible outcome for the patient during the transfer process.
Impella® Device Support During High-Risk Unprotected Left Main Percutaneous Coronary Intervention Demonstrates Favorable Safety and Efficacy Outcomes
Reference: Schreiber T et al. Catheter Cardiovasc Interv. 2017;90(4):576-581. The use of prophylactic Impella® device support during unprotected left main (ULM) percutaneous coronary intervention (PCI) is safe and effective for improving hemodynamic variables in high-risk, non-cardiogenic shock (CS) patients, according to findings from a large, single-center, retrospective review of the USpella registry from Schreiber et … Continue reading “Impella® Device Support During High-Risk Unprotected Left Main Percutaneous Coronary Intervention Demonstrates Favorable Safety and Efficacy Outcomes”
Dr. Tim Larkin of Edward Hospital describes his weaning protocol for the Impella RP® during this physician Q&A session. In this session, Dr. Larkin explains the utility of the pulmonary artery pulsatility index for gauging appropriate weaning time for the Impella RP. Dr. Larkin also recommends monitoring serum lactate for assessing tissue perfusion prior to … Continue reading “Impella RP® Weaning Recommendations from Dr. Tim Larkin”
Dr. Thorsten Siess, Abiomed’s CTO and Inventor of Impella® Shares his Insights on the Impella® Platform of Devices
Dr. Thorsten Siess, Abiomed’s Chief Technology Officer and inventor of Impella® discusses how the world’s smallest heart pump transformed from a product to a platform. Listen in to learn how the Abiomed team is developing new features to satisfy the clinician community’s needs. What new features are being developed by Dr. Siess now? Press play … Continue reading “Dr. Thorsten Siess, Abiomed’s CTO and Inventor of Impella® Shares his Insights on the Impella® Platform of Devices”
Key Takeaways Patients undergoing high-risk PCI often require additional hemodynamic support, particularly with the help of ventricular assist devices. There is no significant difference between Impella 2.5® and IABP in terms of bleeding risk and vascular complications. High-risk patients with acute coronary syndrome (ACS) often require additional cardiac support during a protected percutaneous coronary intervention … Continue reading “IABP vs Impella®: Incidence of Bleeding and Vascular Complications”
High-risk heart disease patients who present major abnormalities may be too weak for open-heart surgery; however, the utilization of certain techniques and devices may circumvent such medical challenges. Patients too weak for surgery who undergo a percutaneous coronary intervention (PCI), for example, have been treated in conjunction with the placement of Impella® . One case … Continue reading “Patients Too Weak for Surgery May Benefit from Heart Pumps”
Percutaneous Insertion and Removal of Impella® Using the Axillary Artery for Treatment of Advanced Peripheral Artery Disease
Dr. Aaron Grantham of St. Luke’s Mid American Heart Institute shares an Impella case of an 80 year old woman with 3 vessel disease, moderate aortic stenosis, EF of 20% and 99% ostial calcified occlusion in RCA. Tweet this, subscribe or find educational opportunities near you.